Increased glycemic variability has been proposed as an independent predictor of hypoglycemia
in diabetic patients. Likewise, episodes of dysglycemia have been found to be predictive of
diabetes in antibodypositive nondiabetic individuals. We hypothesise that an in-depth
observational study comparing state-of-the-art measures of functional beta cell mass and
glycemic variability will specify the relationship between both variables over a broad range
of residual function and will identify treatment goals for functional beta cell mass to be
reached in future beta cell therapy trials in order to avoid frequent hypoglycemia in
patients and dysglycemia in risk groups. The available expertise and infrastructure (see
background and (inter)national context) place the promoters of the present project in a
unique position to carry out the planned experiments and support their feasibility.
Phase:
N/A
Details
Lead Sponsor:
AZ-VUB
Collaborators:
University Hospital, Antwerp University Hospital, Ghent Vrije Universiteit Brussel